Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans
- 1 February 1993
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 67 (2) , 863-875
- https://doi.org/10.1128/jvi.67.2.863-875.1993
Abstract
We have used an indirect-capture enzyme-linked immunosorbent assay to quantitate the reactivity of sera from human immunodeficiency virus type 1 (HIV-1)-infected humans with native recombinant gp120 (HIV-1 IIIB or SF-2) or with the gp120 molecule (IIIB or SF-2) denatured by being boiled in the presence of dithiothreitol with or without sodium dodecyl sulfate. Denaturation of IIIB gp120 reduced the titers of sera from randomly selected donors by at least 100-fold, suggesting that the majority of cross-reactive anti-gp120 antibodies present are directed against discontinuous or otherwise conformationally sensitive epitopes. When SF-2 gp120 was used, four of eight serum samples reacted significantly with the denatured protein, albeit with ca. 3- to 50-fold reductions in titer. Only those sera reacting with denatured SF-2 gp120 bound significantly to solid-phase-adsorbed SF-2 V3 loop peptide, and none bound to IIIB V3 loop peptide. Almost all antibody binding to reduced SF-2 gp120 was blocked by preincubation with the SF-2 V3 loop peptide, as was about 50% of the binding to native SF-2 gp120. When sera from a laboratory worker or a chimpanzee infected with IIIB were tested, the pattern of reactivity was reversed, i.e., there was significant binding to reduced IIIB gp120, but not to reduced SF-2 gp120. Binding of these sera to reduced IIIB gp120 was 1 to 10% that to native IIIB gp120 and was substantially decreased by preincubation with IIIB (but not SF-2) V3 loop peptide. To analyze which discontinuous or conformational epitopes were predominant in HIV-1-positive sera, we prebound monoclonal antibodies (MAbs) to IIIB gp120 and then added alkaline phosphatase-labelled HIV-1-positive sera. MAbs (such as 15e) that recognize discontinuous epitopes and compete directly with CD4 reduced HIV-1-positive sera binding by about 50%, whereas neutralizing MAbs to the C4, V2, and V3 domains of gp120 were either not inhibitory or only weakly so. Thus, antibodies to the discontinuous CD4-binding site on gp120 are prevalent in HIV-1-positive sera, antibodies to linear epitopes are less common, most of the antibodies to linear epitopes are directed against the V3 region, and most cross-reactive antibodies are directed against discontinuous epitopes, including regions involved in CD4 binding.Keywords
This publication has 68 references indexed in Scilit:
- In Vitro Inhibition of a Variety of Human Immunodeficiency Virus Isolates by a Broadly Reactive, V3-Directed Heteroconjugate AntibodyThe Journal of Infectious Diseases, 1992
- Delineation of Immunoreactive, Conserved Regions in the External Glycoprotein of the Human Immunodeficiency Virus Type 1AIDS Research and Human Retroviruses, 1992
- A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activityResearch in Virology, 1991
- Evaluation of monoclonal antibodies to HIV-1 by neutralization and serological assaysAIDS, 1991
- A Phase I Evaluation of the Safety and Immunogenicity of Vaccination with Recombinant gp160 in Patients with Early Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1991
- Epitopes of human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins recognized by antibodies in the sera of HIV-1-infected individualsClinical Immunology and Immunopathology, 1991
- Conserved Sequence and Structural Elements in the HIV-1 Principal Neutralizing DeterminantScience, 1990
- C-Terminal Fragments of gpl20 and Synthetic Peptides from Five HTLV-III Strains: Prevalence of Antibodies to the HTLV-III-MN Isolate in Infected IndividualsAIDS Research and Human Retroviruses, 1990
- Predominance of HIV-1 serotype distinct from LAV-1/HTLV-IIIBThe Lancet, 1990
- Sensitive ELISA for the gp120 and gp160 Surface Glycoproteins of HIV-1AIDS Research and Human Retroviruses, 1988